CILIATECH
- 26/04/2023
- Series A
- $3,841,000
CILIATECH is a medtech company specialized in ophthalmology, developing a new class of implant to address the increasing need to treat glaucoma durably and with almost zero adverse effects.
Founded in 2017 by ophthalmic surgeon and inventor Philippe Sourdille, and Olivier Benoit, a veteran engineer and biotech entrepreneur, CILIATECH developed the CID (Cilio-scleral Inter-positioning Device) groundbreaking concept
CID is the first implant in the industry to reduce IntraOcular Pressure (IOP) without penetrating the anterior chamber or creating subconjunctival filtration. The implant is applicable as a standalone procedure for glaucoma, an aging disease that, globally, affects 80M people per year; or it can be combined with cataract removal. The company is located near Annecy, France.
www.cilia.tech
- Industry Medical Equipment Manufacturing
- Website https://www.cilia.tech/
- LinkedIn https://www.linkedin.com/company/ciliatech/
Related People
Olivier BENOITFounder
Industrial Engineer graduated from INSA Lyon in 1997, I started working in Société Médicale de Précision in Geneva, a subsidiary of Corneal Group where I installed the manufacturing activities for Intra-Ocular Lenses. In 1999, I joined Corneal Industry in Pringy – France where I cumulated successful responsibilities into the manufacturing of Intra-Ocular lenses and hyaluronic acid based products, until being appointed as Manufacturing Manager at end 2000.
Late 2002, with a group of former Corneal employees I founded ANTEIS in which I was appointed as Chief Operations Officer. I was in charge of settling the company, developing the initial products, organizing the manufacturing activities including installation of 2 new factories in compliance to the most stringent applicable standards. I was in charge of the technical development, and more specifically of the US registration for intra-dermal medical devices through PMA. At the end 2009 I was given the charge of Global Regulatory Affairs and at the same time transitioned to Managing Director Healthcare. In that position I am henceforth entirely dedicated to the marketing and sales development for Ophthalmology and Orthopedic products.
Since beg. of 2013 I am also in charge of managing and developing B2B agreements and license-out relations with 3rd parties for all the products of the company.
Starting nov. 2'013, I am heading Aptissen as CEO position, ensuring smooth and complete spin-off from ANTEIS and taking care of the product and business development of the Company.
After a year off, I fall into entrepreneurship again and found CILIATECH in end 2'017, a startup dedicated to medical devices development for surgical ophthalmology and glaucoma surgery.